| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 公司主要从事医药产品及保健食品研发、生产及销售，业务范围涵盖化学制剂、生物制品、化学原料药及中间体、中药制剂、诊断试剂及设备、保健食品等多重领域。丰富的产品阵容及品类为公司获取了更多的市场机会及发展空间。 经过多年的发展，公司已经成为涵盖化学制剂、生物制品、化学原料药及中间体、中药制剂、诊断试剂及设备、保健食品等多重领域的综合性制药企业。化学制剂为公司第一大收入来源，其中消化道用药、促性激素用药等为公司传统优势品种，重点产品长期稳占全国药品制剂细分市场前列，呼吸系统用药及精神用药为公司近年重点布局品种，重点产品销售增长势头强劲。 公司凭借扎实的研发生产实力和稳健的市场推广能力，成功入选2022年度中国化药企业TOP100排行榜前10名。 | ||||||||||||||||||||||||
| Main Business | 从事医药产品及保健食品研发、生产及销售. | ||||||||||||||||||||||||
| Legal Representative | 朱保国 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 朱一帆 | ||||||||||||||||||||||||
| Solicitors | 北京市中伦律师事务所 | ||||||||||||||||||||||||
| Auditors | 瑞华会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0755-86252656;0755-86252388 | ||||||||||||||||||||||||
| Fax No | 0755-86252165 | ||||||||||||||||||||||||
| Website | www.joincare.com | ||||||||||||||||||||||||
| joincare@joincare.com；zhaofengguang@joincare.com；lihongtao@joincare.com；luoxiao@joincare.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 08/06/2001 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.758 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.180 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 7.374 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 20.935B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |